Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Galapagos NV (GLPG)

159.72   3.61 (2.31%) 10-15 09:31
Open: 153.55 Pre. Close: 156.11
High: 160.16 Low: 159.72
Volume: 5,676 Market Cap: 9925M
Galapagos NV is a clinical-stage biotechnology company. It is engaged in the discovery and development of small molecule medicines which address unmet medical conditions.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 157.288 - 157.912 157.912 - 158.45
Low: 151.786 - 152.556 152.556 - 153.218
Close: 154.778 - 156.036 156.036 - 157.12

Technical analysis

as of: 2019-10-14 4:46:44 PM
Overall:       
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 189.69     One year: 221.56
Support: Support1: 151.06    Support2: 144.05
Resistance: Resistance1: 162.41    Resistance2: 189.69
Pivot: 152.98
Moving Average: MA(5): 155.15     MA(20): 154.51
MA(100): 151.68     MA(250): 123.56
MACD: MACD(12,26): -1.94     Signal(9): -2.84
Stochastic oscillator: %K(14,3): 76.15     %D(3): 68.25
RSI: RSI(14): 49.54
52-week: High: 191.63  Low: 85.00  Change(%): 60.8
Average Vol(K): 3-Month: 12338  10-Days: 11064

Price, moving averages and Bollinger Bands

Price and moving averages has closed above its Short term moving average. Short term moving average is currently below mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
GLPG has closed below upper band by 26.4%. Bollinger Bands are 36.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

2019-09-02
Gilead Sciences Deal With Galapagos NV Should Be A Winner
Gilead has already partnered with Galapagos for filgotinib. Gilead is using a lot of cash for the deal, but it is a cash generator. The potential value of thera

2019-08-29
Galapagos NV (GLPG) Upgraded to Buy: Here's What You Should Know
Galapagos NV (GLPG) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Financial Analysis

Growth
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Click here to get more fundamental analysis.
Tweet this page Share on Facebook
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  Nasdaq Global Select
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 61.95
Shares Float (M) 37.11
% Held by Insiders
% Held by Institutions 16.78
Shares Short (K) 743
Shares Short P. Month (K)

Stock Financials

EPS -1.690
Book Value (p.s.) 25.490
PEG Ratio
Profit Margin -20.37
Operating Margin
Return on Assets (ttm) -3.7
Return on Equity (ttm) -6.5
Qtrly Rev. Growth 18.5
Gross Profit (p.s.) 2.967
Sales Per Share
EBITDA (p.s.)
Qtrly Earnings Growth
Operating Cash Flow (M)
Levered Free Cash Flow (M)

Stock Valuations

P/E -92.37
P/E Growth Ratio
P/BV 6.12
P/S
P/CF

Dividends & Splits

Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Forward Dividend
Last Split Date
Last Split Ratio -1e+010
7 Binary Options
Your Ad Here
android_stock_chart
Stock Chart
stoxline_lite
Stoxline Lite
stoxline_pro
Stoxline Pro
Option_Calculator
Option Calculator
(c) 2006-2019 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.